Compounds for inhibition of alpha 4 beta 7 integrin

Abstract

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

1 - 53 . (canceled) 
     
     
         54 . A method for treating an inflammatory disease or condition associated with α4β7 integrin, comprising administrating to a subject in need thereof an effective amount of a pharmaceutical composition comprising a compound of formula (I): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein:
 X 1  and X 2  are each independently selected from C, and N; wherein the bond between X 1  and X 2  is a single or a double bond; 
 X 3  and X 4  are each independently selected from CR 10 , and N; 
 X 6  and X 7  are each independently selected from CR 10 R 10 , CR 10 , S, S(O), S(O) 2 , N, NR 11 , C(O), and O; 
 each X 6  is independently selected from CR 10 R 10 , CR 10 , S, S(O), S(O) 2 , N, NR 11 , C(O), and O;
 wherein the bond between X 5  and X 6 , X 6  and X 6 , or X 6  and X 7  is a single or a double, provided that at least one is a double bond; 
 
 R 1  is selected from -L-A 1 , -L-A 2 , -L-A 3 , and -L-A 4 ;
 L is selected from a bond, —O—, —O—C(O)—*, —NH—, —C(O)—N(H)—*, and —N(H)—C(O)—*; 
 wherein * indicates a point of attachment of L to A 1 , A 2 , A 3 , or A 4 ; 
 A 1  is C 6-10 aryl optionally substituted with one to six R a ; 
 A 2  is 5-10 membered heteroaryl containing one to five heteroatoms independently selected from S, N, and O, and optionally one or two C(O); wherein A 2  is optionally substituted with one to six R a ; 
 A 3  is 5-10 membered cycloalkyl or 5-14 membered heterocyclyl; wherein A 3  is optionally substituted with one to six R a ; and 
 A 4  is —NR a1 R a2 ;
 wherein each R a  is independently selected from halo, cyano, hydroxyl, —NR a1 R a2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxyl, C 1-6 haloalkyl, C 1-6 haloalkoxyl, —S(O) m —C 1-6 alkyl, C 3-8 cycloalkyl, 3-6 membered heterocyclyl, C 6-10 aryl, 5-6 membered heteroaryl, —O-(3-6 membered heterocyclyl), —O—C 1-4 alkylene-C 3-8 cycloalkyl, —O-phenyl, and —O—C 3-8 cycloalkyl;
 each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxyl, C 1-6 haloalkyl, C 1-6 haloalkoxyl, and —S(O) m —C 1-6 alkyl of R a  are optionally substituted with one to three R a3 ; wherein each R a3  is independently selected from hydroxyl, cyano, —NR a1 R a2 , C 1-6 alkoxyl, C 3-8 cycloalkyl, phenyl, and 3-6 membered heterocyclyl; wherein each C 3-8 cycloalkyl, phenyl, and 3-6 membered heterocyclyl of R a3  is independently optionally substituted with one to three R a4 ; 
  wherein each R a4  is independently selected from halo, cyano, hydroxyl, —NR a1 R a2 , C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxyl, C 1-6 haloalkoxyl, C 3-8 cycloalkyl, and 3-6 membered heterocyclyl; and 
 each C 3-8 cycloalkyl, 3-6 membered heterocyclyl, C 6-10 aryl, 5-6 membered heteroaryl, —O-(3-6 membered heterocyclyl), —O—C 1-4 alkylene-C 3-8 cycloalkyl, —O-phenyl, and —O—C 3-8 cycloalkyl of R a  is independently optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NR a1 R a2 , C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxyl, and C 1-6 haloalkoxyl; 
 
 
 
 each R 2 , R 3 , R 4 , R 5 , and R 6  is independently selected from H, halo, cyano, hydroxyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxyl, C 1-8 haloalkyl, C 1-8 haloalkoxyl, —NR b1 R b2 , —R b3 S(O) m R b4 , —S(O) m R b4 , —NR b1 S(O) y R b4 , —COOR b1 , —CONR b1 R b2 , —NR b1 COOR b2 , —NR b1 COR b4 , —R b3 NR b1 R b2 , —S(O) y NR b1 R b2 , C 3-12 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 3-12 membered heterocyclyl;
 each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxyl, C 1-8 haloalkyl, and C 1-8 haloalkoxyl of R 2 , R 3 , R 4 , R 5 , and R 6  is independently optionally substituted with one to two R c ; wherein each R c  is independently selected from azido, oxo, cyano, halo, hydroxyl, —NR a1 R a2 , C 1-4 alkoxyl, C 3-8 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C 3-8 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of R c  is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NR a1 R a2 , C 1-4 alkyl, C 1-6 haloalkyl, C 1-4 alkoxyl, and C 3-6 cycloalkyl; 
 each C 6-10 aryl and 5-6 membered heteroaryl of R 2 , R 3 , R 4 , R 5 , and R 6  is independently optionally substituted with one to five R b ; and 
 each C 3-12 cycloalkyl and 3-12 membered heterocyclyl of R 2 , R 3 , R 4 , R 5 , and R 6  is independently optionally substituted with one to six groups independently selected from ═CR b1 R b2 , and R b ;
 wherein each R b  is independently selected from azido, cyano, halo, hydroxyl, —NR a1 R a2 , C 1-6 alkyl, C 1-8 haloalkyl, C 1-6 alkoxyl, C 3-6 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl;
 wherein each C 3-6 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of R b  is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NR a1 R a2 , C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 alkoxyl; 
 
 
 each R b1  and R b2  is independently selected from H, C 1-8 alkyl, C 1-8 haloalkyl, C 3-8 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 3-8 membered heterocyclyl;
 each C 1-8 alkyl and C 1-6 haloalkyl of R b1  and R b2  is optionally substituted with one to two R b5 ; and 
 each C 3-8 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 3-8 membered heterocyclyl of R b1  and R b2  is independently optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NR a1 R a2 , C 1-8 alkyl, C 1-8 haloalkyl, C 1-6 alkoxyl, C 3-6 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; 
 
 R b3  is C 1-4 alkylene; 
 R b4  is selected from C 1-4 alkyl, C 1-4 haloalkyl, C 3-6 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C 1-4 alkyl, C 1-4 haloalkyl, C 3-8 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and the 4-6 membered heterocyclyl of R b4  is optionally substituted with one to three R b6 ; 
 each R b5  is independently selected from cyano, hydroxyl, C 1-4 alkoxyl, C 3-8 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C 3-8 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of R b5  is optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NR a1 R a2 , C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, and phenyl; and 
 each R b6  is independently selected from halo, cyano, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, C 3-6 cycloalkyl, phenyl, 4-6 membered heterocyclyl, and 5-6 membered heteroaryl; wherein each C 3-6 cycloalkyl, 4-6 membered heterocyclyl, and 5-6 membered heteroaryl of R b6  is independently optionally substituted with one to three groups independently selected from halo, cyano, —NR a1 R a2 , C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 alkoxyl; or 
 
 R 2  and R 3 , R 3  and R 4 , or R 5  and R 6  together with the atoms to which they are attached may form a C 6-10 aryl, 5-6 membered heteroaryl, C 3-6 cycloalkyl, or 5-6 membered heterocyclyl; wherein each C 6-10 aryl, 5-6 membered heteroaryl, C 3-6 cycloalkyl, or 5-6 membered heterocyclyl is optionally substituted with one to three groups independently selected from halo, cyano, —NR a1 R a2 , C 1-6 alkyl, C 1-6 alkoxyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, 3-6 membered heterocyclyl, C 6-10 aryl, 5-6 membered heteroaryl, C 1-4 alkylene-C 3-8 cycloalkyl, C 1-4 alkylene-C 6-10 aryl, and C 1-4 alkylene-(5-6 membered heteroaryl); 
 R 7  is selected from H, C 1-4 alkyl, and C 1-4 haloalkyl; 
 R 8  is selected from H, C 1-4 alkyl, and C 1-4 haloalkyl; 
 R 9  is selected from H, C 1-6 alkyl, —C 1-4 alkylene-NR a1 R a2 , —C 1-4 alkylene-C(O)NR a1 R a2 , —C 1-4 alkylene-O—C(O)—C 1-4 alkyl, —C 1-4 alkylene-O—C(O)—O—C 1-4 alkyl, —C 1-4 alkylene-O—C(O)—C 1-4 alkylene-NR a1 R a2 , —C 1-4 alkylene-O—C 1-4 alkyl, C 3-8 cycloalkyl, —C 1-4 alkylene-C 3-8 cycloalkyl, 4-6 membered heterocyclyl, and —C 1-4 alkylene-(4-6 membered heterocyclyl);
 wherein each C 3-8 cycloalkyl, —C 1-4 alkylene-C 3-8 cycloalkyl, and 4-6 membered heterocyclyl of R 9  is optionally substituted with one to three groups independently selected from halo, C 1-4 alkyl, C 1-4 alkoxyl, and C 1-4 haloalkyl; or 
 
 R 9  together with the N that attaches to R 8  forms a 5 membered heterocyclyl; wherein the 5 membered heterocyclyl is optionally substituted with one to two groups independently selected from halo, C 1-6 alkyl, C 1-6 alkoxyl, C 1-6 haloalkyl, and C 6-10 aryl; wherein C 6-10 aryl is optionally substituted with one to three groups independently selected from halo, C 1-6 alkyl, C 1-6 alkoxyl, and C 1-6 haloalkyl; 
 each R 10  is independently selected from H, halo, cyano, hydroxyl, —C(O)R b1 , —NR a1 R a2 , C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, C 1-4 haloalkoxyl, C 3-10 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl, and 5-6 membered heteroaryl; wherein each C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, C 1-4 haloalkoxyl, C 3-10 cycloalkyl, 3-8-membered heterocyclyl, C 6-10 aryl, and 5-6 membered heteroaryl is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NR a1 R a2 , C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, and C 3-6 cycloalkyl; or 
 two R 10  either attached to the same or adjacent atoms form C 3-12 cycloalkyl or 3-10 membered heterocyclyl; wherein each C 3-12 cycloalkyl and 3-10 membered heterocyclyl is optionally substituted with one to three groups independently selected from H, halo, C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, and C 1-4 haloalkoxyl; 
 each R 11  is independently selected from H, C 1-4 alkyl, and C 1-4 haloalkyl; wherein each C 1-4 alkyl, —C(O)R b1 , and C 1-4 haloalkyl of R 11  is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NR a1 R a2 , C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, and C 3-6 cycloalkyl; or 
 R 10  and R 11 , or two R 11  together with the atoms to which they are attached to form 3-12 membered heterocyclyl; wherein 3-12 membered heterocyclyl is optionally substituted with one to three groups independently selected from H, halo, C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, and C 1-4 haloalkoxyl; 
 each R a1  and R a2  is independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; 
 p is selected from 1, 2, and 3; 
 m is selected from 0, 1, and 2; 
 v is selected from 1 and 2; 
 
       provided that the ring formed by Y and Z is not one of 
       
         
           
           
               
               
           
         
       
       wherein * indicates a point of attachment to R 1 ; and 
       at least one pharmaceutically acceptable carrier. 
     
     
         55 . The method of  claim 54 , wherein the inflammatory disease or condition is selected from inflammatory bowel disease (IBD), Ulcerative colitis (UC), Crohn's disease, graft-versus-host disease (GVHD), and primary sclerosing cholangitis (PSC). 
     
     
         56 . The method of  claim 54 , further comprising at least one or more additional therapeutic agents. 
     
     
         57 . The method of  claim 56 , wherein the at least one or more therapeutic agents are independently selected from JAK tyrosine kinase inhibitors, Tumor Progression Locus 2 (TPL2) inhibitors, Toll-like receptor 8 (TLR8) inhibitors, and IRAK4 inhibitors. 
     
     
         58 . The method of  claim 57 , wherein the at least one or more additional therapeutic agent is a JAK tyrosine kinase inhibitor and wherein the JAK tyrosine kinase inhibitor is fligotinib.